A $10 million milestone payment is the headline number, but the more revealing figure sits behind it: Nurix has now pulled approximately $139 million from its 2019 collaboration with Sanofi while still holding eligibility for roughly $453 million in future milestones tied to the STAT6 program alone. The trigger for this latest payment is the initiation of a Phase 1 first-in-human trial of SAR448272/NX-3911, an oral small-molecule degrader targeting STAT6, a transcription factor that sits at the convergence of IL-4 and IL-13 signaling. That positioning matters clinically because STAT6 is not a peripheral node in type 2 inflammation; it is the shared downstream effector through which both cytokines drive pathology in atopic dermatitis, asthma, and related diseases.
The mechanistic logic of targeting STAT6 directly, rather than blocking its upstream cytokine signals, is what separates this program from the injectable biologics that currently dominate the space. Dupilumab, for instance, works by inhibiting the IL-4 receptor alpha subunit to blunt both IL-4 and IL-13 signaling, an approach that requires subcutaneous injection. SAR448272 is oral, and as a degrader it eliminates STAT6 protein rather than simply blocking its activity, a distinction that could prove important in tissues where simple inhibition leaves residual function intact. Whether that translates into a clinical advantage over the growing roster of approved biologics for atopic dermatitis is precisely what Phase 1 will begin to address, first through safety and pharmacokinetics, then through early signals of target engagement and degradation depth.
Sanofi holds sole responsibility for conducting the trial, which keeps Nurix’s cash runway insulated from development costs at this stage. Nurix retains a co-development and co-promotion option in the United States that can be exercised after clinical proof of concept, a structure that lets the company observe efficacy data before committing capital to a larger share of the program. The DEL-AI platform that generated SAR448272 is also active across partnerships with Gilead and Pfizer, meaning the STAT6 data will carry platform-level implications beyond this single asset.
The clearest near-term signal to track is the Phase 1 dose-escalation readout on STAT6 protein levels in accessible compartments, likely peripheral blood mononuclear cells. Robust degradation at tolerated doses would validate the oral degrader approach in immunology and sharpen the case for Nurix exercising its U.S. co-promotion option, a decision that would signal far more conviction in the program than any milestone payment announcement can.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
